DL-Cystine
Need Assistance?
  • US & Canada:
    +
  • UK: +

DL-Cystine

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

DL-Cystine is a non-essential amino acid used as a nutritional and dietary supplement.

Category
DL-Amino Acids
Catalog number
BAT-003585
CAS number
923-32-0
Molecular Formula
C6H14N2O4S2
Molecular Weight
240.30
DL-Cystine
IUPAC Name
2-amino-3-[(2-amino-2-carboxyethyl)disulfanyl]propanoic acid
Synonyms
Cystine; NSC 203781; (H-DL-Cys-OH)2; 3,3'-Dithio-bis(2-aminopropionic acid); 3,3'-disulfanediylbis(2-aminopropanoic acid); Dicysteine; (±)-3,3'-Dithiobis(2-aminopropionic acid); 2-Amino-3-[(2-amino-2-carboxyethyl)dithio]propanoic acid; Bis(β-amino-β-carboxyethyl) disulfide
Related CAS
349-46-2 (D-isomer) 56-89-3 (L-isomer)
Appearance
White to off-white crystalline powder
Purity
≥95%
Density
1.358 g/cm3(estimate)
Melting Point
>177°C (dec.)
Boiling Point
468.2±45.0 °C(Predicted)
Storage
Store at RT
Solubility
Soluble in Aqueous Acid (Slightly, Heated), Aqueous Base
InChI
InChI=1S/C6H12N2O4S2/c7-3(5(9)10)1-13-14-2-4(8)6(11)12/h3-4H,1-2,7-8H2,(H,9,10)(H,11,12)
InChI Key
LEVWYRKDKASIDU-UHFFFAOYSA-N
Canonical SMILES
C(C(C(=O)O)N)SSCC(C(=O)O)N

DL-Cystine is an amino acid with various applications in health, beauty, and research. Here are some key applications of DL-Cystine:

Dietary Supplements: DL-Cystine is commonly used in dietary supplements to promote overall health and wellness. It plays a crucial role in the formation of keratin, a structural protein in hair and skin. These supplements help in strengthening hair, enhancing skin elasticity, and supporting immune system functions.

Cosmetic Industry: In the cosmetic industry, DL-Cystine is incorporated into hair care and skincare products. Its ability to strengthen hair shafts and improve hair texture makes it a popular ingredient in shampoos and conditioners. Additionally, it is used in skincare formulations to enhance skin hydration and improve the appearance of fine lines and wrinkles.

Pharmaceutical Applications: DL-Cystine has therapeutic applications, particularly in the management of liver conditions and detoxification processes. Its antioxidant properties help in neutralizing harmful free radicals and protecting liver cells from oxidative damage. It is also studied for its potential benefits in enhancing immune functions and accelerating recovery in certain health conditions.

Biochemical Research: DL-Cystine is utilized in biochemical research to study protein structure and function. It is involved in the formation of disulfide bonds, which are crucial for maintaining protein stability and function. Researchers use DL-Cystine to investigate protein folding mechanisms and the role of cystine residues in protein interactions and cellular processes.

1. D-cystine utilization by the chick
D H Baker, J M Harter Poult Sci . 1978 Mar;57(2):562-3. doi: 10.3382/ps.0570562.
Young chicks were fed graded levels of either L-cystine or DL-cystine in a purified crystalline amino acid diet made adequate in methionine but void in cystine. Gain performance and slope-ratio efficacy comparisons indicated that the D-isomer of cystine could not be utilized by the chick.
2. Selenium induces a multi-targeted cell death process in addition to ROS formation
Marita Wallenberg, Aristi P Fernandes, Mikael Björnstedt, Valentina Gandin, Cristina Marzano, Sougat Misra, Agata M Wasik J Cell Mol Med . 2014 Apr;18(4):671-84. doi: 10.1111/jcmm.12214.
Selenium compounds inhibit neoplastic growth. Redox active selenium compounds are evolving as promising chemotherapeutic agents through tumour selectivity and multi-target response, which are of great benefit in preventing development of drug resistance. Generation of reactive oxygen species is implicated in selenium-mediated cytotoxic effects on cancer cells. Recent findings indicate that activation of diverse intracellular signalling leading to cell death depends on the chemical form of selenium applied and/or cell line investigated. In the present study, we aimed at deciphering different modes of cell death in a single cell line (HeLa) upon treatment with three redox active selenium compounds (selenite, selenodiglutathione and seleno-DL-cystine). Both selenite and selenodiglutathione exhibited equipotent toxicity (IC50 5 μM) in these cells with striking differences in toxicity mechanisms. Morphological and molecular alterations provided evidence of necroptosis-like cell death in selenite treatment, whereas selenodiglutathione induced apoptosis-like cell death. We demonstrate that selenodiglutathione efficiently glutathionylated free protein thiols, which might explain the early differences in cytotoxic effects induced by selenite and selenodiglutathione. In contrast, seleno-DL-cystine treatment at an IC50 concentration of 100 μM induced morphologically two distinct different types of cell death, one with apoptosis-like phenotype, while the other was reminiscent of paraptosis-like cell death, characterized by induction of unfolded protein response, ER-stress and occurrence of large cytoplasmic vacuoles. Collectively, the current results underline the diverse cytotoxic effects and variable potential of redox active selenium compounds on the survival of HeLa cells and thereby substantiate the potential of chemical species-specific usage of selenium in the treatment of cancers.
3. Insights into the molecular basis for substrate binding and specificity of the fungal cystine transporter CgCYN1
Monika Sharma, Anup Arunrao Deshpande, Anand Kumar Bachhawat Biochim Biophys Acta Biomembr . 2017 Nov;1859(11):2259-2268. doi: 10.1016/j.bbamem.2017.08.020.
Cystine transporters are a clinically important class of transporters found in bacteria, pathogenic fungi and mammalian cells. Despite their significance, very little is known about the mechanism of substrate recognition and transport. We have carried out studies on the plasma membrane Candida glabrata cystine transporter, CgCYN1 a member of the amino acid-polyamine-organocation (APC) transporter superfamily. A homology model of CgCYN1 was generated by using crystal structures of three known bacterial APC transporters followed by further refinement using molecular dynamics simulations. This revealed a possible translocation channel lined by TMD1, TMD3, TMD6, TMD8 and TMD10 helices. In silico docking studies with cystine along with comparison with other known cystine permeases and closely related lysine permeases allowed prediction of amino acid residues specifically involved in cystine binding. To validate this model a total of 19 predicted residues were subjected to site directed mutagenesis and functionally evaluated by growth on cystine and the analogues cystathionine and seleno-dl-cystine. Biochemical evaluation by radioactive uptake assays confirmed that these mutants showed reduced cystine uptake. Detailed kinetic analysis studies for the transport defective mutants revealed the involvement of residue G255 from the conserved FAYGGTE motif of TMD 6, and T339, S340 and H347 (all from TMD 8) in cystine binding. The implications of these findings on the homologous mammalian cystine transporter, XcT are also discussed.
Online Inquiry
Verification code
Inquiry Basket